EAEduardo Agustin Arias-Sánchez

Eduardo Agustin Arias-Sánchez

*This is an algorithmically generated author record based on publicly available information.

Eduardo Agustin Arias-Sánchez has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Amit Bhan

    Barts Heart Centre, St Bartholomew's Hospital London, UK

    2 shared publications
  • Fabio Solis-Jimenez

    Instituto Nacional de Cardiologia, Mexico City, Mexico

    2 shared publications
  • Gian Manuel Jiménez-Rodríguez

    Interventional Cardiology Department, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico

    2 shared publications
  • Guering Eid-Lidt

    Department of Interventional Cardiology, National Institute of Cardiology Ignacio Chávez , Juan Badiano 1, Belisario Dominguez Secc 16, Tlalpan, 14080 Mexico City

    2 shared publications
  • Hugo Rodríguez-Zanella

    Echocardiography Department, “Ignacio Chávez” National Institute of Cardiology, Juan Badiano No. 1 Tlalpan, 14080 Mexico City, Mexico

    2 shared publications
  • Juan Pablo Sandoval

    Interventional Cardiology Department, “Ignacio Chávez” National Institute of Cardiology, Juan Badiano No. 1 Tlalpan, 14080 Mexico City, Mexico

    2 shared publications

Latest Publications

  • Open Access

    Effect of empagliflozin on reducing the no-reflow phenomenon in patients with ST-elevation myocardial infarction: rationale and design of the EMPA-PCI trial

    by Fabio Solis-Jimenez, Diego Araiza-Garaygordobil, Jessy Steve Masso-Bueso, Alejandro Villalobos-Ordaz, Fernando Arellano-Juvera, Federico Arredondo-Aragon, Gabriela Melendez-Ramirez, Rafael Valdez-Ortiz, Sergio Martin Alday-Ramirez, Hugo Gerardo Rodriguez-Zanella, et al.

    Introduction: Coronary no-reflow phenomenon occurs when cardiac tissue fails to perfuse normally despite opening of the occluded vessel. It is one of the manifestations of reperfusion injury, a series of pathological conditions associated with an increase in infarct size and adverse clinical outcomes. While there is currently no specific treatment to limit or prevent reperfusion injury, preclinical models have shown promising results with iSGLT2 inhibitors in this regard. However, there are no human studies specifically designed to evaluate the effects of empagliflozin on the no-reflow phenomenon or reperfusion injury. Methods and analysis: The EMPA-PCI is a single-centre, open-label, randomized clinical trial that compares the use of empagliflozin vs. standard treatment in reducing reperfusion injury in patients with STEMI. A total of 162 patients will be randomized to receive either 25 mg of Empagliflozin as a loading dose before angioplasty followed by 10 mg per day for three doses in the treatment group, or standard treatment in the control group. The incidence of the no-reflow phenomenon during PCI, infarct size by magnetic resonance imaging, myocardial injury biomarkers will be compared. Clinical follow-up will be conducted for 3 months following patient enrollment. Conclusion: Empagliflozin administered prior to PCI in patients with STEMI may contribute to prevent the no-reflow phenomenon and limit reperfusion injury. This could provide new insights into the cardiovascular benefits already known for SGLT2 inhibitors. Trial registration: ClinicalTrials registry. NCT06342141.


  • Open Access

    Anticoagulant versus Antiplatelet Therapy After Acute Coronary Syndromes in Patients with Coronary Artery Ectasia: A Retrospective Cohort Study

    by Fabio Solis-Jiménez, Ximena Latapi-Ruiz Esparza, Hannah Priscila Guzman-Solorzano, Monserrat Villalobos-Pedroza, Luis Angel Morales-Villamil, Braiana Angeles Diaz-Herrera, Sarai Hernandez-Pastrana, Rodrigo Gopar-Nieto, Eduardo A. Arias-Sanchez, Luis Alfonso Marroquín-Donday, et al.

    Purpose: Patients with coronary ectasia (CAE) have an increased risk of major cardiovascular events (MACE). Current preventive treatments are uncertain, with oral anticoagulants often prescribed based on limited retrospective studies. Our aim is to help address the question: what is the most appropriate treatment? Methods: Using a retrospective cohort of patients with an ACS and CAE in a single center in Mexico City, two groups were observed based on the treatment at discharge: dual antiplatelet therapy (group 1) and anticoagulation with either a VKA or a DOAC, regardless of antiplatelet therapy (group 2). The main outcome was MACE, which was a composite of all-cause mortality, reinfarction, and ischemic stroke at 4.5 years follow-up. Results: A total of 354 patients admitted for ACS and CAE were included. 228 (64.4%) patients were classified in the DAPT group and 126 (35.5%) in the anticoagulants group. The DAPT group had higher type 2 diabetes rates, NSTEMI presentation, and lower-grade ectasia. The anticoagulation group had higher STEMI presentation and higher-grade ectasia. The DAPT group had 33 (14.5%) events of MACE, whereas the anticoagulation group had 16 (13.1%) events. Anticoagulants were not associated with a risk reduction of the primary endpoint (HR 0.95; 95% CI, 0.47–1.54; p =  0.59), nor any of the individual components. Conclusion: This retrospective cohort study showed similar effectiveness between DAPT and anticoagulation in patients with ACS and CAE for preventing MACE, and lower bleeding risk. Further research is needed to identify optimal candidates for each antithrombotic regime. Graphical DAPT: double antiplatelet therapy, HR: hazard ratio


  • Open Access

    Left atrial veno-arterial extracorporeal membrane oxygenation in post-myocardial infarction ventricular septal defect with cardiogenic shock: a case report

    by Gian Manuel Jiménez-Rodríguez, Gustavo Rojas-Velasco, Eduardo A Arias-Sánchez, Daniel Manzur-Sandoval, Norman Said Vega-Servin, Ricardo-Eduardo Quirazco-Cordova, Guering Eid-Lidt

    Background: Ventricular septal defect (VSD) complicating acute myocardial infarction (MI) represents a life-threatening condition and has a mortality of >90% if left untreated. Case summary: A 53-year-old man with a prior medical history of diabetes and hypertension presented with cardiogenic shock secondary to VSD as a mechanical complication of non-reperfused inferior MI. Discussion: The choice of mechanical support can be difficult in this type of patient. Given the risk of an increased shunt because of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and the increase in left ventricle (LV) afterload, several measures were taken to plan the best ECMO configuration. Given the absence of any real improvement in the LV and an elevated residual ratio between pulmonary and systemic flow (Qp/Qs), the final decision was to switch to left atrial VA-ECMO (LAVA-ECMO). The use of LAVA-ECMO improved the patient’s haemodynamics and allowed his condition to stabilize; LAVA-ECMO is feasible and may be effective as a mechanical circulatory support (MCS) strategy for patients in cardiogenic shock due to VSD as a mechanical complication of acute MI.


  • Multimodality imaging with 3D echocardiography transillumination and 3D CT rendering for a ventricular septal rupture’s morphological analysis

    by Hugo Rodríguez-Zanella, Juan Pablo Sandoval, Xochitl A Ortiz-León, Ivan Hernández-Mejía, Eduardo A Arias

    Ventricular septal rupture (VSR) complicating an acute myocardial infarction poses a challenge for cardiovascular imagers, interventionists, and surgeons, given its complex and heterogeneous morphology. We present an example of multimodality imaging evaluation with non-invasive techniques in a 52-year patient with a VSR. Three-dimensional transthoracic echocardiography (3DTTE) using Flexilight (PanelsA and B) revealed a spherical posterior-basal rupture of 17 × 10 mm with a perimeter of 4.5 cm. 3D computed tomography (CT) cinematic rendering displayed an 18 × 11 mm rupture in the basal region and posterior position with a perimeter of 4.6 cm with unfavourable posterior borders for percutaneous closure alongside a sizable basal aneurysm...

  • Novel Cinematic Rendering Use for Ventricular Septal Ruptures

    by Eduardo A. Arias, Juan Pablo Sandoval, Julio I. Farjat-Pasos, Hugo Rodríguez-Zanella, Regina de la Mora-Cervantes


  • Open Access

    ISCHEMIA Trial and the Significance of MI

    by Eduardo A Arias, Félix Damas-De Los Santos, Heriberto Ontiveros-Mercado

    During the past decade, the treatment of choice for chronic coronary syndromes (CCS) has been a contentious issue. Whether revascularisation, either percutaneous or surgical, or optimal medical therapy, offers better prognosis in terms of mortality, MI, and symptom relief, has yet to be confirmed. The long-awaited and recently published International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial randomised more than 5,000 patients into a revascularisation plus optimal medical therapy group and an optimal medical therapy alone group. The authors analyse the trial, with particular emphasis on the incidence of MI. They propose a patient-centred approach to incorporate the results of the ISCHEMIA trial into daily practice and determine the best treatment strategy for patients with CCS.


  • Open Access

    Left main-like bifurcation primary percutaneous coronary intervention case report: anomalous right coronary artery ostium from the left anterior descending

    by Julio I Farjat Pasos, Jorge Padilla Ibarra, Paolo Angelini, Eduardo A Arias

    Background: A single coronary artery ostium (SCAO) is estimated to be present in 0.066% of the general population. The proximal coronary course and the relationship with surrounding structures are related to malignant vs. benign prognoses. We present a case of SCAO with the right coronary artery (RCA) arising from the mid-left anterior descending (LAD), complicated by anterior and inferior STEMI because of acute thrombotic occlusion at the bifurcation and its percutaneous management. Case summary: A 56-year-old male was admitted with sudden onset of resting chest pain. His ECG showed an anterior, inferior, and right ventricular STEMI. Via trans-radial access, coronary angiography showed significant stenoses at the left main and the circumflex but also a thrombotic occlusion at the proximal segment of the LAD while no RCA was seen. After crossing the LAD occlusion, the dominant RCA appeared from the mid-LAD. A provisional stent technique was performed achieving good results. Coronary computed tomography angiography showed an SCAO congenital anomaly with a patent stent in the bifurcation accompanied by diffuse coronary artery disease causing mild stenosis of the left main, proximal, and distal circumflex. Discussion: The RCA arising from the mid-LAD with pre-pulmonic course has been described in only 37 cases. One reported an LAD/RCA bifurcation treatment with two stents technique in a stable scenario. The present is the first case reported of an acute thrombotic occlusion of an LAD/RCA bifurcation clinically resulting in a left main equivalent STEMI treated successfully with primary percutaneous coronary intervention using a bifurcation technique.


  • Ecocardiograma de contraste con burbujas en ablación septal con alcohol

    by Eduardo A. Arias, Marco Antonio Peña-Duque, Marco Antonio Martínez-Ríos

  • Bubble Contrast Echocardiography for Alcohol Septal Ablation

    by Eduardo A. Arias, Marco Antonio Peña-Duque, Marco Antonio Martínez-Ríos


  • Open Access

    TAVI for Pure Native Aortic Regurgitation: Are We There Yet?

    by Eduardo A Arias, Amit Bhan, Zhan Y Lim, Michael Mullen

    Treatment of degenerative aortic stenosis has been transformed by transcatheter aortic valve implantation (TAVI) over the past 10–15 years. The success of various technologies has led operators to attempt to broaden the indications, and many patients with native valve aortic regurgitation have been treated ‘off label’ with similar techniques. However, the alterations in the structure of the valve complex in pure native aortic regurgitation are distinct to those in degenerative aortic stenosis, and there are unique challenges to be overcome by percutaneous valves. Nevertheless some promise has been shown with both non-dedicated and dedicated devices. In this article, the authors explore some of these challenges and review the current evidence base for TAVI for aortic regurgitation.